Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
78,238.24
(
0.79%
)
News Focus
News Focus
Post# of 822942
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biosectinvestor

Send PM Follow Ignore
Followers 200
Posts 25597
Boards Moderated 0
Alias Born 04/03/2010

biosectinvestor

Re: HyGro post# 521997

Friday, 10/14/2022 7:58:18 PM

Friday, October 14, 2022 7:58:18 PM

Post# of 822942
Novocure is a cash rush operating company with revenues. Of course NWBO is a company approaching that stage but is not yet there, should be there soon.

The US FDA appears to me to be well aware of DCVax-L and it’s challenges as indicated in the side article on ECA’s and certain references therein to trials that would be exactly like the DCVax-L trial. I don’t believe it is likely that DCVax-L will lack approval in any of the markets in which it had a trial and I believe the approval will be expedited once all the details are resolved and filed. Just IMHO.

I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News